Author(s): Sami Ali, Rana Makhous

Email(s): samikherro123@gmail.com , rana.makhous@tishreen.edu.sy

DOI: 10.52711/0974-360X.2022.00084   

Address: Sami Ali1, Rana Makhous2
1Master Student, Department of Pharmacology and Toxicology, Tishreen University, Latakia, Syria.
2Professor, Department of Pharmacology and Toxicology, Tishreen University, Latakia, Syria.
*Corresponding Author

Published In:   Volume - 15,      Issue - 2,     Year - 2022


ABSTRACT:
Objective: The aim of this study was to evaluate the effect of simvastatin on the bone remolding markers in rats (experimental study). Materials and methods: The study involved 18 male Wistar rats, they were divided into three groups: Group I (n=6; control group), Group II (n=6; was administrated 7.5 mg/kg/ dexamethasone intra muscular for 2 months served as a model of osteoporosis [op]), Group III (n=6;was administered 7.5 mg/kg/ dexamethasone intra muscular for 2month and treated orally with 8mg/kg of simvastatin).After 8 weeks, serum acid phosphatase was determined for the three group. Results: The levels of serum acid phosphatase were notably elevated in the [op] group. Administration of simvastatin produced a significant decrease in the levels of serum acid phosphatase. Conclusion: simvastatin was able to decrease the rate of bone resorption in an animal model of osteoporosis induced by dexamethasone.


Cite this article:
Sami Ali, Rana Makhous. Evaluation of the effect of Simvastatin Therapy on Bone remodeling in Rats. Research Journal of Pharmacy and Technology. 2022; 15(2):525-8. doi: 10.52711/0974-360X.2022.00084

Cite(Electronic):
Sami Ali, Rana Makhous. Evaluation of the effect of Simvastatin Therapy on Bone remodeling in Rats. Research Journal of Pharmacy and Technology. 2022; 15(2):525-8. doi: 10.52711/0974-360X.2022.00084   Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-2-4


REFERENCES:
1.    Sakat Bhagyashri T. Sakhare R B. Suryvanshi U C. Kore P S. Mohite S K. Magdum C S. Osteoporosis: The Brittle Bone. Asian J. Pharm. Res. 2018; 8(1):39-43. doi: 10.5958/2231-5691.2018.00008.4
2.    Chitra V. Mohammed Anwar Ali M. Animal Models for Osteoporosis-A Review. Research J. Pharm. and Tech 2020; 13(3):1543-1548. doi.org/10.5958/0974-360X.2020.00280.2
3.    Famili P. Cauley J. Suzuki JB. Weyant R Longitudinal study of periodontal disease and edentulism with rates of bone loss in older women. J Periodontol. 2005; 76(1):11–15. doi.org /10.1902/jop.2005.76.1.11
4.    O’Neill TW. Felsenberg D. Varlow J. Cooper C. Kanis JA. Silman AJ The prevalence of vertebral deformity in European men and women: the European vertebral osteoporosis study. J Bone Miner Res. 1996; 11(7):1010–1018. doi.org/10.1002/jbmr.5650110719
5.    Khoshnood Z. Anoosheh M. Haji Zadej E A Description of Osteoporosis Preventive Behaviors in Iranian Adolescent Girls. Asian J. Nur. Edu. and Research. 2016; 6(1): 1-4. doi: 10.5958/2349-2996.2016.00001.X
6.    Zerzour .A Haddig N. Derouiche S Analysis of Osteoporosis risk factors in Menopausal women's of Algeria population. Asian J. Res. Pharm. Sci. 2020; 10(2):79-84. doi.org/10.5958/2231-5659.2020.00015.6
7.    Rossini M. Adami S. Bertoldo F et al Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo. 2016; 68(1):1–39. doi.org/ 10.4081/reumatismo.2016.870
8.    Radhakrishna B. Ashok M. Harish PL. Veera Jyothsna M. Shivalinge Gowda KP Current and Future Trends of Drugs Used in Osteoporosis. Research J. Pharmacology and Pharmacodynamics. 2011; 3(6): 329-333.
9.    Hajime M. Okada Y. Mori H. Tanaka Y A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. J Bone Miner Metab. 2014; 32(5):601–604. doi.org/10.1007/s00774-014-0564-z
10.    Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int. 2010; 86(6):421–435. doi.org/10.1007/s00223-010-9364-1
11.    Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009; 8(2):96–110. doi.org/ 10.14310/horm.2002.1226    
12.    Moraes LA. Vaiyapuri S. Sasikumar P et al Antithrombotic actions of statins involve PECAM-1 signaling. Blood. 2013;122(18):3188–3196. doi.org/10.1182/blood-2013-04-491845
13.    Hatzigeorgiou C. Jackson JL. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int. 2005;16(8):990–998. doi.org/10.1007/s00198-004-1793-0
14.    Ganesh Akula. Bollaboina Venkatesh. Sanjayraj K. Phanindra S S. Jaswanth A. Validated RP-HPLC Method for the Simultaneous Estimation of Simvastatin and Niacin. Asian J. Research Chem. 9(2): Feb., 2016; Page 62-66. doi: 10.5958/0974-4150.2016.00011.0
15.    Nakkala Balaji. Sai Kishore V. Kasani Hari Krishna Gouda. Formulation and Evaluation of Simvastatin Solid Dispersions for Dissolution Rate Enhancement. Research J. Pharma. Dosage Forms and Tech. 2011; 3(4): 152-156.
16.    Abdul Sayeed. Sheshgiri Gada. Mallikarjun B K Formulation and Development of Gastric Floating Drug Delivery Systems of Simvastatin. Research J. Pharm. and Tech.3 (4): Oct.-Dec.2010; Page 1252-1259.
17.    Sangram M P. Rakesh V. Mishra Satish V S Development and Evaluation of Sustain Release Simvastatin Pellets. Research J. Pharm. and Tech. 2017; 10(8): 2467-2473. doi: 10.5958/0974-360X.2017.00436.X
18.    Singh S R. Jadhav K R. Tripathi P K Novel Floating Insitu gel of Antihyperlipidemic agent. Research J. Pharm. and Tech. 2019; 12(3): 1086-1090. doi: 10.5958/0974-360X.2019.00178.1
19.    Jadhav SB. Jain GK Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol. 2006 ;58(1):3–18. doi.org/10.1211/jpp.58.1.0002
20.    Ayukawa Y. Okamura A. Koyano K Simvastatin promotes osteogenesis around titaniumimplants: A histological and histometrical study in rats. Clinical oral implants research. 2004; 15(3): 346-350. doi.org/10.1046/j.1600-0501.2003.01015.x
21.    Uzzan B. Cohen r. Nicolas P et al Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone. 2007; 40: 1581-1587. doi.org/10.1016/j.bone.2007.02.019
22.    Athanasios N T. Dokos C. Georgia D K et al Statins, bone formation and osteoporosis: hope or hype. Hormones. 2012; 11(2):126-139. doi. org/ 10.14310/horm.2002.1339
23.    Sobhani A. Moradi F. Pasbakhsh P et al Effects of Glucocorticoid on Bone Metabolism Markers and Bone Mineral Density in Rats. Frontiers in Dentistry. 2005; 2(2):64-69
24.    El-Nabarawi, N. El-Wakd M. Salem M. Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study. Drug design, development and therapy. 2017; 11: p. 1383_1391. doi.org/10.2147/DDDT.S133020
25.    Mundy G. Garrett R. Harris S et al Stimulation of bone formation in vitro and in rodents by statins. Science.1999; 286(5446):1946–1949. doi.org/10.1126/science.286.5446.1946
26.    Wong RW. Rabie AB Statin collagen grafts used to repair defects in the parietal bone of rabbits. Br J Oral Maxillofac Surg. 2003; 41(4): 244–248. doi.org/10.1016/s0266-4356(03)00081-0
27.    Anbinder AI. Balducci I. Rocha RF. Carvalho YR Influence of simvastatin on density defects in the parietal. RPG Rev Pós-Grad. 2002; 9(4):331–336. doi.org/10.1590/s0103-64402006000400001
28.    Lin S. Huang J. Fu Z. et al The effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in high-fat-fed ovariectomized rats. Calcif Tissue Int. 2015; 96(6):541–551. doi.org/10.1007/s00223-015-9975-7
29.    Maeda T. Matsunuma A. Kurahashi I. Yanagawa T. Yoshida H. Horiuchi N Induction of osteoblast differentiation indices by statins in MC3T3-E1 Cells. J Cell Biochem. 2004; doi.org/92(3):458–471. 10.1002/jcb.20074
30.    Hughes A. Rogers MJ. Idris AI. Crockett JC A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. Calcif Tissue Int. 2007; 81(5):403–413. doi.org/10.1007/s00223-007-9078-1
31.    An T. Hao J. Sun S et al Efficacy of statins for osteoporosis: a systematic review and meta-analysis.Osteoporosis International. 2017; 28(1):47-57. doi.org/10.1007/s00198-016-3844-8

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available